Professor Kevin Marsh is the Director of the Kenya Medical Research Institute (KEMRI) Wellcome Trust programme in Kilifi, Kenya, head of the molecular parasitology group, and Professor of Tropical Medicine at the University of Oxford. He leads a large programme of clinical, laboratory and epidemiological research on a wide range of infectious diseases. Professor Marsh has a broad research interest in tropical medicine, ranging from the burden of infectious diseases in African children to a specific focus on the immune epidemiology of malaria. He has published over 300 peer-reviewed papers and sits on multiple global health advisory groups.
Click here to read a recent interview from the Guardian newspaper.
Professor Andrew Pollard is Professor of Paediatric Infection and Immunity at Oxford University and Honorary Consultant Paediatrician at the Children's Hospital, Oxford, UK. He leads a research group (The Oxford Vaccine Group) working on clinical trials of new and improved vaccines for the prevention of infection in children and a laboratory group involved in enhancing the understanding of immunity and the development of new vaccines. He is also the director of the postgraduate diploma in paediatric infectious diseases at Oxford University.
Professor Paul Keim is the Director of Pathogen Genomics at the Translational Genomics Research Institute, the Regent’s Professor of Biology and the Cowden Endowed Chair of Microbiology in the Department of Biological Science at Northern Arizona University. His research focuses on the genomic analysis, phylogeny and evolutionary biology of dangerous bacterial pathogens, particularly Bacillus anthracis, Burkholderia pseudomallei and more recently Staphylococcus aureus. He is one of the world’s leading experts on microbial forensics and played a key role in the investigation of the 1993 Aum Shinrikyo and 2001 US anthrax attacks.
Dr. David Nicolau is Director for the Center for Anti-Infective Research and Development and Coordinator for Research in the Department of Medicine, Division of Infectious Diseases and Pharmacy, at Hartford Hospital in Hartford, Connecticut. David Nicolau’s research activities involve a wide range of preclinical drug development studies to assess the in vitro potency, in vivo efficacy and toxicity profiles of novel compounds. He has been a principal investigator for Phase I – IV studies, as well as Investigational New Drug applications. Dr Nicolau is also widely recognized for his efforts focusing on the development of antimicrobial utilization strategies to improve outcomes and reduce the cost of care in the infected patient.